Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Annette Hasenburg Prof., Dr, med

Annette Hasenburg Prof., Dr, med

Director, Obstetrics and Gynecology, Mainz University Medical Center, Mainz, Germany

Dr. Annette Hasenburg is the Director of Obstetrics and Gynecology at Mainz University Medical Center in Mainz, Germany. She is Head of the ESGO (European Society of Gynaecologic Oncology) Task Force Psycho-Oncology and is on the board of directors of the Institute of Sexuality and Health of the University Freiburg in Freiburg, Germany.

Dr. Hasenburg received her medical degree from Ruhr-University, Bochum, Germany, where she also received residency training in internal medicine (Evangelisches Krankenhaus Herne) and obstetrics and gynecology (Marienhospital Herne). She received specialist training and qualification in psychotherapy at the Institute of Psychotherapy and Psychosomatic Medicine in Düsseldorf. She completed a postdoctoral fellowship in the Department of Obstetrics and Gynecology, Oncology Division, at Baylor College of Medicine in Houston, Texas.

Since 2018, Dr. Hasenburg has been on the Board of Directors of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie) and since 2020 on the Board of Directors of the DGGG (Deutsche Gesellschaft Gynäkologie und Geburtshilfe).

Disclosures

  • Honoraria: AstraZeneca; Celgen; GSK; LEO Pharma; MedConcept GmbH; Med update GmbH; Medicultus; Pfizer; Promedicis GmbH; Softconsult; Roche Pharma AG; Streamedup! GmbH; Tesaro Bio Germany GmbH
  • Advisory roles: AstraZeneca; GSK; LEO Pharma; PharmaMar; Promedicis GmbH; Roche Pharma AG; Tesaro Bio Germany GmbH; MSD (Merck Sharp & Dohme) GmbH

Recent Contributions to PracticeUpdate:

  1. Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone for Platinum-Resistant Recurrent Ovarian Cancer
  2. ASCO 2022: Abstract Recommendations From Prof. Dr. Annette Hasenburg for Gynecologic Oncology
  3. Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer
  4. Cytoreductive Surgery for Relapsed Ovarian Cancer
  5. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
  6. ASCO 2021: Abstract Recommendations From Dr. Annette Hasenburg for Gynecologic Cancer
  7. Secondary Cytoreduction Followed by Chemotherapy vs Chemotherapy Alone in Platinum-Sensitive Relapsed Ovarian Cancer
  8. Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer
  9. Impact of Lymphadenectomy on Sexual Function Among Ovarian Cancer Patients
  10. 2020 Top Stories in Oncology: DESKTOP III: Surgery for Recurrent Ovarian Cancer

Elsewhere

Most Read This Week

Recently Updated